Eric H Rubin

Eric H Rubin

UNVERIFIED PROFILE

Are you Eric H Rubin?   Register this Author

Register author
Eric H Rubin

Eric H Rubin

Publications by authors named "Eric H Rubin"

Are you Eric H Rubin?   Register this Author

57Publications

1183Reads

47Profile Views

Correction: The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor.

Oncogene 2019 Aug;38(35):6322

Department of Pharmacology, the Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-019-0874-7DOI Listing
August 2019

Optimal two-stage designs for exploratory basket trials.

Contemp Clin Trials 2019 Jun 29:105807. Epub 2019 Jun 29.

Biostatistics and Research Decision Sciences, Merck & Co., Inc, Kenilworth, NJ 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cct.2019.06.021DOI Listing
June 2019

A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development.

Contemp Clin Trials 2018 01 28;64:238-242. Epub 2017 Sep 28.

Oncology Early Development, Merck & Co., Inc., Kenilworth, NJ 07033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cct.2017.09.006DOI Listing
January 2018

Strategies to Maximize Patient Participation in Clinical Trials.

Am Soc Clin Oncol Educ Book 2017 ;37:216-221

From the Merck Research Laboratories, North Wales, PA; Pinkie Hugs, LLC, Washington, DC; U.S. Food and Drug Administration, Silver Spring, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_179803DOI Listing
December 2017

Report on the Third FDA-AACR Oncology Dose-Finding Workshop.

Cancer Immunol Res 2017 12;5(12):1058-1061

U.S. Food and Drug Administration, Silver Spring, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-17-0590DOI Listing
December 2017

Dose Finding Versus Speed in Seamless Immuno-Oncology Drug Development.

J Clin Pharmacol 2017 10;57 Suppl 10:S143-S145

Quantitative Pharmacology and Pharmacometrics, PPDM, Kenilworth, NJ, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcph.1001
Publisher Site
http://dx.doi.org/10.1002/jcph.1001DOI Listing
October 2017

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Clin Cancer Res 2017 09;23(17):4980-4991

Drug Development Program, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-3064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736967PMC
September 2017

How many tumor indications should be initially screened in development of next generation immunotherapies?

Contemp Clin Trials 2017 08 21;59:113-117. Epub 2017 Mar 21.

Department of Oncology, Lombardi Comprehensive Cancer Center, Innovation Center for Biomedical Informatics, Georgetown University Medical Center, 2115 Wisconsin Avenue, Suite 110, Washington, DC 20007, USA; Department of Biostatistics, Bioinformatics, and Biomathematics, Lombardi Comprehensive Cancer Center, Innovation Center for Biomedical Informatics, Georgetown University Medical Center, 2115 Wisconsin Avenue, Suite 110, Washington, DC 20007, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cct.2017.03.012DOI Listing
August 2017

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 Oct;34(30):3638-3647

Vassiliki Papadimitrakopoulou, J. Jack Lee, Ignacio I. Wistuba, Anne S. Tsao, Frank V. Fossella, Neda Kalhor, Sanjay Gupta, Lauren Averett Byers, Julie G. Izzo, Ximing Tang, Ferdinandos Skoulidis, Don L. Gibbons, Li Shen, Caimiao Wei, Lixia Diao, S. Andrew Peng, Jing Wang, Alda L. Tam, John V. Heymach, and Waun Ki Hong, The University of Texas MD Anderson Cancer Center, Houston, TX; Scott N. Gettinger, Sarah B. Goldberg, Ja Seok Koo, and Roy S. Herbst, Yale University, New Haven, CT; Vincent A. Miller, Foundation Medicine, Cambridge, MA; Kevin R. Coombes, Ohio State University College of Medicine, Columbus, OH; and David J. Mauro and Eric H. Rubin, Merck, North Wales, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.0084DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065110PMC
October 2016

Developing precision medicine in a global world.

Clin Cancer Res 2014 Mar;20(6):1419-27

Authors' Affiliations: Merck Research Laboratories, North Wales, Pennsylvania; Friends of Cancer Research, Arlington, Virginia; NorthShore University Health System Pathology and Laboratory Medicine, Evanston, Illinois; and Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0091DOI Listing
March 2014

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.

Cancer Chemother Pharmacol 2013 Sep 3;72(3):493-508. Epub 2013 Jul 3.

Department of Project Leadership and Management, Merck Sharp & Dohme Corp. a Subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2220-zDOI Listing
September 2013

A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors.

Cancer 2012 Sep 31;118(17):4262-70. Epub 2012 Jan 31.

Department of Medical Oncology, University of Miami and Sylvester Comprehensive Cancer Center, Miami, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27428DOI Listing
September 2012

Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials.

Clin Cancer Res 2012 Feb;18(3):638-44

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314693PMC
February 2012

Drug development and clinical trials--the path to an approved cancer drug.

Nat Rev Clin Oncol 2012 Feb 28;9(4):215-22. Epub 2012 Feb 28.

Merck Research Laboratories, 351 North Sumneytown Pike, North Wales, PA 19454, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2012.22
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2012.22DOI Listing
February 2012

Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.

Clin Cancer Res 2011 Nov;17(21):6634-40

Department of Medicine, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College, New York, New York, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-11-1105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853353PMC
November 2011

The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development.

Cancer Discov 2011 Jun 1;1(1):17-20. Epub 2011 Jun 1.

Merck Research Laboratories, North Wales, Pennsylvania 19454, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8274.CD-11-0036DOI Listing
June 2011

Introducing new strategies in...

Clin Cancer Res 2010 Mar 23;16(5):1347. Epub 2010 Feb 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-0236DOI Listing
March 2010

Finding the right dose for cancer therapeutics--can we do better?

Clin Cancer Res 2010 Feb 9;16(4):1085-7. Epub 2010 Feb 9.

Merck Research Laboratories, North Wales, Pennsylvania 19454, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-3246DOI Listing
February 2010

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

Clin Cancer Res 2009 Jun 9;15(12):4213-9. Epub 2009 Jun 9.

The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0360DOI Listing
June 2009

Identification of phosphorylation sites of TOPORS and a role for serine 98 in the regulation of ubiquitin but not SUMO E3 ligase activity.

Biochemistry 2008 Dec;47(52):13887-96

Departments of Pharmacology and Medicine, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, New Jersey 08901, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi801904qDOI Listing
December 2008

Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.

Invest New Drugs 2008 Jun 18;26(3):205-13. Epub 2007 Oct 18.

Department of Pharmacology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-007-9093-0
Publisher Site
http://dx.doi.org/10.1007/s10637-007-9093-0DOI Listing
June 2008

Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.

Anticancer Drugs 2008 Apr;19(4):411-20

Departments of Medicine and Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08903, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0b013e3282f5218bDOI Listing
April 2008

Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1.

J Biol Chem 2008 Feb 12;283(8):4834-40. Epub 2007 Dec 12.

Department of Biological Sciences, University of Maryland, Baltimore County, Baltimore, Maryland 21250, USA.

View Article

Download full-text PDF

Source
http://www.jbc.org/content/283/8/4834.full.pdf
Web Search
http://www.jbc.org/cgi/doi/10.1074/jbc.M708630200
Publisher Site
http://dx.doi.org/10.1074/jbc.M708630200DOI Listing
February 2008

TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins.

J Proteome Res 2007 Oct 6;6(10):3918-23. Epub 2007 Sep 6.

Department of Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, New Jersey 08901, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/pr0703674DOI Listing
October 2007

Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors.

Clin Cancer Res 2007 Oct;13(19):5876-82

The Cancer Institute of New Jersey, University of Medicine & Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-07-0883DOI Listing
October 2007

A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies.

Cancer Chemother Pharmacol 2006 Jun 18;57(6):789-95. Epub 2005 Oct 18.

The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, NJ 08901, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-005-0125-1DOI Listing
June 2006

Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway.

Cancer Res 2006 Jan;66(2):921-8

Department of Pharmacology, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-05-1123DOI Listing
January 2006

Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.

J Clin Oncol 2005 Dec 21;23(36):9120-9. Epub 2005 Nov 21.

Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.03.0981DOI Listing
December 2005

Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53.

J Biol Chem 2004 Aug 9;279(35):36440-4. Epub 2004 Jul 9.

Department of Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08901, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.C400300200DOI Listing
August 2004

The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor.

Oncogene 2004 Jul;23(31):5293-300

Department of Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1207700DOI Listing
July 2004

Epothilones: mechanism of action and biologic activity.

J Clin Oncol 2004 May;22(10):2015-25

Department of Medicine, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.12.001DOI Listing
May 2004

Development of a bioanalytical liquid chromatography method for quantitation of 9-nitrocamptothecin in human plasma.

J Chromatogr B Analyt Technol Biomed Life Sci 2004 Jan;799(1):63-72

Department of Pharmacology, Robert Wood Johnson School of Medicine, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08901, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchromb.2003.10.010DOI Listing
January 2004

Mechanisms of resistance to topoisomerase I-targeting drugs.

Oncogene 2003 Oct;22(47):7296-304

The Cancer Institute of New Jersey, Department of Molecular and Cellular Pharmacology, UMDNJ-Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 08901, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/1206935
Publisher Site
http://dx.doi.org/10.1038/sj.onc.1206935DOI Listing
October 2003

Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.

Clin Cancer Res 2003 Jul;9(7):2504-9

Division of Medical Oncology, Department of Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Jersey 08903, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/9/7/2504.full.
Web Search
July 2003

Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.

Cancer Res 2003 Jun;63(12):3228-33

Department of Pharmacology, Cancer Institute of New Jersey, Robert Wood Johnson-University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08901, USA.

View Article

Download full-text PDF

Source
June 2003

Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.

Clin Cancer Res 2003 May;9(5):1673-9

Department of Medicine, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick 08901, USA.

View Article

Download full-text PDF

Source
May 2003

Transcription-dependent degradation of topoisomerase I-DNA covalent complexes.

Mol Cell Biol 2003 Apr;23(7):2341-50

Department of Pharmacology, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC150741PMC
http://dx.doi.org/10.1128/mcb.23.7.2341-2350.2003DOI Listing
April 2003

The topoisomerase I-binding RING protein, topors, is associated with promyelocytic leukemia nuclear bodies.

Exp Cell Res 2002 Jul;277(2):152-60

Department of Pharmacology, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903-2681, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1006/excr.2002.5550DOI Listing
July 2002